Associate Professor Branka Grubor-Bauk

Externally-Funded Research Fellow (D)

Adelaide Medical School

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

My Research
Career
Publications
Grants and Funding
Supervision
Contact

A/Prof Grubor-Bauk is the Head of Viral Immunology at the Adelaide Medical School. She trained as a virologist, immunologist, and vaccine scientist and after postdoctoral training and a period in Biotech, she now leads a collaborative research program which encompasses discovery and translational science components. Viral Immunology group is involved in a number of different commercial research partnerships, with an aim to develop solutions with clinical application.

The lab is focused on evaluation of immunity to viral infections and on the development of novel vaccines against Zika virus, hepatitis C, JEV, WNV and dengue- as well as SARS-CoV-2, employing various cutting edge techniques in viral vaccine design and development.

Our team has broad experience in animal models, including infection models, in vitro and in vivo vaccine validation assays (antigen presentation, B, T cell assays, in vivo epitope mapping, fluorescent target array assay), multi-parametric flow cytometry, antibody and cytokine assays (ELISA, neutralisation assays, intracellular cytokine staining).

Student projects

Viral Immunology Group has student projects available for Honours, Masters and PhD studies. The projects cover vaccine development (mRNA, DNA) with options for cross-discipline and industry collaborations. Other projects focus on pathology of Zika virus during pregnancy and development of novel vaccines to prevent Zika virus induced congenital fetal malformations. Immunology projects are done in collaboration with various clinicians and scientists and are focused on investigations into long COVID and different aspects of COVID-19 immunity in severely ill patients, convalescent, vaccinated and immunocompromised individuals.

Prospective students can contact Branka directly via email with any further questions. Students should have sound knowledge of immunology in order to undertake these projects.

Available projects:

1) Development of multivalent mRNA vaccines against HCV

2) Liver immunobiology in HCV vaccine development

3) Murray Valley encephalitis virus vaccine development

4) Novel mRNA-LNP formulations for optimal vaccine immunogenicity and tissue targeting

5) Immunopathogenesis of Zika virus in animal models of pregnancy

6) COVID-19 Clinical Immunology projects:

- Long-COVID,

- severe/critical COVID19

Language Competencies

Language Competency
English -
Serbian -

Language	Competency
English	-
Serbian	-

Education

Date	Institution name	Country	Title
2007	University of Adelaide, Adelaide	Australia	PhD
1999	University of Adelaide, Adelaide	Australia	Bachelor of Health Sciences (Honours)
1998	University of Adelaide, Adelaide	Australia	Bachelor of Science

Journals

Year	Citation
2023	Ryan, F. J., Norton, T. S., McCafferty, C., Blake, S. J., Stevens, N. E., James, J., . . . Lynn, D. J. (2023). A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines.. Cell Rep Med, 4(3), 1-26. DOI Scopus8 WoS1 Europe PMC5
2023	Zhang, W., Kedzierski, L., Chua, B. Y., Mayo, M., Lonzi, C., Rigas, V., . . . Christensen, B. (2023). Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities.. Nature Immunology, 24(6), 966-978. DOI Scopus7 WoS2 Europe PMC3
2023	Williams, C. M. D., Noll, J. E., Bradey, A. L., Duggan, J., Wilczek, V. J., Masavuli, M. G., . . . Panagopoulos, V. (2023). Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma. British Journal of Haematology, 203(4), 614-624. DOI
2022	Balachandran, H., Phetsouphanh, C., Agapiou, D., Adhikari, A., Rodrigo, C., Hammoud, M., . . . Bull, R. A. (2022). Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses. Cell Reports, 38(6), 19 pages. DOI Scopus27 WoS23 Europe PMC23
2022	Ryan, F. J., Hope, C. M., Masavuli, M. G., Lynn, M. A., Mekonnen, Z. A., Yeow, A. E. L., . . . Lynn, D. J. (2022). Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Medicine, 20(1), 26-1-26-23. DOI Scopus132 WoS91 Europe PMC104
2022	Perkins, G. B., Tunbridge, M., Salehi, T., Chai, C. S., Kireta, S., Johnston, J., . . . Coates, P. T. (2022). Concurrent vaccination of kidney transplant recipients and close household cohabitants against COVID-19. Kidney International, 101(5), 1077-1080. DOI Scopus7 WoS5 Europe PMC5
2022	Garcia-Valtanen, P., Hope, C. M., Masavuli, M. G., Yeow, A. E. L., Balachandran, H., Mekonnen, Z. A., . . . Grubor-Bauk., B. (2022). SARS-CoV-2 Omicron variant escapes neutralising antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents.. Cell Reports Medicine, 3(6), 23 pages. DOI Scopus20 WoS15 Europe PMC19
2022	Tunbridge, M., Perkins, G. B., Singer, J., Salehi, T., Ying, T., Grubor-Bauk, B., . . . Coates, P. T. (2022). Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)-rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipients.. Trials, 23(1), 780. DOI Scopus5 WoS1 Europe PMC3
2022	Adhikari, A., Abayasingam, A., Rodrigo, C., Agapiou, D., Pandzic, E., Brasher, N. A., . . . COSIN Study Group. (2022). Longitudinal Characterization of Phagocytic and Neutralization Functions of Anti-Spike Antibodies in Plasma of Patients after Severe Acute Respiratory Syndrome Coronavirus 2 Infection.. J Immunol, 209(8), 1499-1512. DOI Scopus1 Europe PMC1
2021	Abayasingam, A., Balachandran, H., Agapiou, D., Hammoud, M., Rodrigo, C., Keoshkerian, E., . . . COSIN study group. (2021). Long-term persistence of RBD-positive memory B cells encoding neutralising antibodies in SARS-CoV-2 infection. Cell Reports Medicine, 2(4), 100228-1-100228-14. DOI Scopus50 WoS47 Europe PMC45
2021	Garcia-Valtanen, P., Hope, C. M., Masavuli, M. G., Yeow, A. E. L., Balachandran, H., Mekonnen, Z. A., . . . Grubor-Bauk, B. (2021). COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection. DOI
2021	Ryan, F. J., Hope, C. M., Masavuli, M. G., Lynn, M. A., Mekonnen, Z. A., Lip Yeow, A. E., . . . Lynn, D. J. (2021). Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. DOI
2020	Gummow, J., Masavuli, M., Mekonnen, Z. A., Li, Y., Wijesundara, D. K., Shrestha, A. C., . . . Grubor-Bauk, B. (2020). Safety profile of a multi-antigenic DNA vaccine against hepatitis C virus. Vaccines, 8(1), 1-15. DOI Scopus6 WoS4 Europe PMC4
2020	Fenix, K., Wijesundara, D. K., Cowin, A. J., Grubor-Bauk, B., & Kopecki, Z. (2020). Immunological Memory in Imiquimod-Induced Murine Model of Psoriasiform Dermatitis.. Int J Mol Sci, 21(19), 13 pages. DOI Scopus19 WoS14 Europe PMC7
2020	Mekonnen, Z. A., Masavuli, M. G., Yu, W., Gummow, J., Whelan, D. M., Al-Delfi, Z., . . . Grubor-Bauk, B. (2020). Enhanced T cell responses induced by a necrotic dendritic cell vaccine, expressing HCV NS3. Front Microbiol, 11, 1-13. DOI Scopus5 WoS3 Europe PMC2
2019	Roy, S., Jaeson, M., Li, Z., Mahboob, S., Jackson, R., Grubor-Bauk, B., . . . Ranasinghe, C. (2019). Viral vector and route of administration determine the ILC and DC profiles responsible for downstream vaccine-specific immune outcomes. Vaccine, 37(10), 1266-1276. DOI Scopus15 WoS14 Europe PMC13
2019	Mekonnen, Z. A., Grubor-Bauk, B., Masavuli, M. G., Shrestha, A. C., Ranasinghe, C., Bull, R. A., . . . Wijesundara, D. K. (2019). Toward DNA-based T-cell mediated vaccines to target HIV-1 and hepatitis C virus: approaches to elicit localized immunity for protection. Frontiers in Cellular and Infection Microbiology, 9(APR), 1-8. DOI Scopus10 WoS7 Europe PMC4
2019	Shrestha, A. C., Wijesundara, D. K., Masavuli, M. G., Mekonnen, Z. A., Gowans, E. J., & Grubor-Bauk, B. (2019). Cytolytic perforin as an adjuvant to enhance the immunogenicity of DNA vaccines. Vaccines, 7(2), 14 pages. DOI Scopus10 WoS11 Europe PMC7
2019	Masavuli, M. G., Wijesundara, D. K., Underwood, A., Christiansen, D., Earnest-Silveira, L., Bull, R., . . . Grubor-Bauk, B. (2019). A hepatitis C virus DNA vaccine encoding a secreted, oligomerized form of envelope proteins is highly immunogenic and elicits neutralizing antibodies in vaccinated mice. Frontiers in immunology, 10(MAY), 1-19. DOI Scopus29 WoS24 Europe PMC21
2019	Christiansen, D., Earnest-Silveira, L., Grubor-Bauk, B., Wijesundara, D. K., Boo, I., Ramsland, P. A., . . . Torresi, J. (2019). Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery. Scientific Reports, 9(1), 1-13. DOI Scopus43 WoS33 Europe PMC25
2019	Mekonnen, Z. A., Grubor-Bauk, B., English, K., Leung, P., Masavuli, M. G., Shrestha, A. C., . . . Wijesundara, D. K. (2019). Single-dose vaccination with a hepatotropic adeno-associated virus efficiently localizes T cell immunity in the liver with the potential to confer rapid protection against Hepatitis C virus. Journal of Virology, 93(19), e00202-19-1-e00202-19-19. DOI Scopus8 WoS8 Europe PMC8
2019	Grubor-Bauk, B., Wijesundara, D. K., Masavuli, M., Abbink, P., Peterson, R. L., Prow, N. A., . . . Gowans, E. J. (2019). NS1 DNA vaccination protects against Zika infection through T cell-mediated immunity in immunocompetent mice.. Sci Adv, 5(12), eaax2388. DOI Scopus47 WoS36 Europe PMC34
2018	Christiansen, D., Earnest-Silveira, L., Chua, B., Meuleman, P., Boo, I., Grubor-Bauk, B., . . . Torresi, J. (2018). Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine. Scientific Reports, 8(1), 6483-1-6483-13. DOI Scopus32 WoS26 Europe PMC23
2018	Wijesundara, D., Gummow, J., Li, Y., Yu, W., Quah, B., Ranasinghe, C., . . . Grubor-Bauk, B. (2018). Induction of genotype-cross reactive, hepatitis C virus-specific cell mediated immunity in DNA-vaccinated mice. Journal of Virology, 92(8), 1-15. DOI Scopus19 WoS19 Europe PMC19
2018	Christiansen, D., Earnest-Silveira, L., Chua, B., Boo, I., Drummer, H. E., Grubor-Bauk, B., . . . Torresi, J. (2018). Antibody responses to a quadrivalent Hepatitis C viral-like particle vaccine adjuvanted with Toll-like receptor 2 agonists. Viral Immunology, 31(4), 1-6. DOI Scopus9 WoS8 Europe PMC6
2017	Wijesundara, D., Yu, W., Quah, B., Eldi, P., Hayball, J., Diener, K., . . . Grubor-Bauk, B. (2017). Cytolytic DNA vaccine encoding lytic perforin augments the maturation of- and antigen presentation by- dendritic cells in a time-dependent manner. Scientific Reports, 7(1), 8530-1-8530-8. DOI Scopus7 WoS7 Europe PMC6
2017	Wijesundara, D., Ranasinghe, C., Grubor-Bauk, B., & Gowans, E. (2017). Emerging targets for developing T cell-mediated vaccines for human immunodeficiency virus (HIV)-1. Frontiers in Microbiology, 8(OCT), 2091-1-2091-7. DOI Scopus10 WoS9 Europe PMC7
2017	Masavuli, M., Wijesundara, D., Torresi, J., Gowans, E., & Grubor-Bauk, B. (2017). Preclinical development and production of virus-like particles as vaccine candidates for hepatitis C. Frontiers in Microbiology, 8(DEC), 11 pages. DOI Scopus26 WoS19 Europe PMC18
2016	Canavese, M., Wijesundara, D., Maddern, G. J., Grubor-Bauk, B., & Hauben, E. (2016). Hepatitis C virus drives the pathogenesis of hepatocellular carcinoma: From immune evasion to carcinogenesis. Clinical and Translational Immunology, 5(10), e103. DOI Scopus9 Europe PMC5
2016	Canavese, M., Wijesundara, D., Maddern, G., Grubor-Bauk, B., & Hauben, E. (2016). Hepatitis C virus drives the pathogenesis of hepatocellular carcinoma: from immune evasion to carcinogenesis.. Clin Transl Immunology, 5(10), 1-6. DOI WoS9 Europe PMC10
2016	Tomusange, K., Wijesundara, D., Gummow, J., Wesselingh, S., Suhrbier, A., Gowans, E., & Grubor-Bauk, B. (2016). Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits potent and protective HIV-specific immune responses. Scientific Reports, 6(1), 36658 -1-36658-11. DOI Scopus10 WoS10 Europe PMC8
2016	Grubor-Bauk, B., Yu, W., Wijesundara, D., Gummow, J., Garrod, T., Brennan, A., . . . Gowans, E. (2016). Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell-mediated immunity in mice and pigs. Gene Therapy, 23(1), 26-37. DOI Scopus24 WoS22 Europe PMC21
2016	Tomusange, K., Wijesundara, D., Gummow, J., Garrod, T., Li, Y., Gray, L., . . . Gowans, E. (2016). A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice. Scientific Reports, 6(1), 29131-1-29131-10. DOI Scopus16 WoS16 Europe PMC14
2016	Jorritsma, S., Gowans, E., Grubor-Bauk, B., & Wijesundara, D. (2016). Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines. Vaccine, 34(46), 5488-5494. DOI Scopus91 WoS79 Europe PMC58
2015	Tomusange, K., Yu, W., Suhrbier, A., Wijesundara, D., Grubor-Bauk, B., & Gowans, E. (2015). Engineering human rhinovirus serotype-A1 as a vaccine vector. Virus Research, 203, 72-76. DOI Scopus7 WoS6 Europe PMC3
2015	Gummow, J., Li, Y., Yu, W., Garrod, T., Wijesundara, D., Brennan, A., . . . Gowans, E. (2015). A multiantigenic DNA vaccine that induces broad hepatitis C virus-specific T-Cell responses in mice. Journal of Virology, 89(15), 7991-8002. DOI Scopus20 WoS22 Europe PMC18
2014	Yu, W., Grubor-Bauk, B., Mullick, R., Das, S., & Gowans, E. J. (2014). Immunocompetent mouse models to evaluate intrahepatic T cell responses to HCV vaccines. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 10(12), 3576-3578. DOI WoS2
2014	Yu, W., Grubor-Bauk, B., Gargett, T., Garrod, T., & Gowans, E. (2014). A novel challenge model to evaluate the efficacy of hepatitis C virus vaccines in mice. Vaccine, 32(27), 3409-3416. DOI Scopus14 WoS13 Europe PMC10
2014	Gargett, T., Grubor-Bauk, B., Miller, D., Garrod, T., Yu, S., Wesselingh, S., . . . Gowans, E. (2014). Increase in DNA vaccine efficacy by virosome delivery and co-expression of a cytolytic protein. Clinical and Translational Immunology, 3(6), e18-1-e18-7. DOI Scopus19 WoS16 Europe PMC15
2014	Yu, W., Grubor-Bauk, B., Mullick, R., Das, S., & Gowans, E. J. (2014). Immunocompetent mouse models to evaluate intrahepatic T cell responses to HCV vaccines. Human vaccines & immunotherapeutics, 10(12), 3576-3578. DOI Scopus3 Europe PMC3
2014	Garrod, T., Grubor-Bauk, B., Yu, S., Gargett, T., & Gowans, E. (2014). Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency.. Human vaccines & immunotherapeutics, 10(9).
2014	Garrod, T., Gargett, T., Yu, W., Major, L., Burrell, C., Wesselingh, S., . . . Gowans, E. (2014). Loss of long term protection with the inclusion of HIV pol to a DNA vaccine encoding gag. Virus Research, 192, 25-33. DOI Scopus6 WoS6 Europe PMC6
2014	Garrod, T., Grubor-Bauk, B., Gargett, T., Li, Y., Miller, D., Yu, W., . . . Gowans, E. (2014). DNA vaccines encoding membrane-bound or secreted forms of heat shock protein 70 exhibit improved potency. European Journal of Immunology, 44(7), 1992-2002. DOI Scopus21 WoS18 Europe PMC14
2014	Garrod, T., Grubor-Bauk, B., Yu, S., Gargett, T., & Gowans, E. (2014). Encoded novel forms of HSP70 or a cytolytic protein increase DNA vaccine potency. Human Vaccines and Immunotherapeutics, 10(9), 2679-2683. DOI Scopus9 WoS10 Europe PMC8
2014	Gargett, T., Grubor-Bauk, B., Garrod, T., Yu, W., Miller, D., Major, L., . . . Gowans, E. (2014). Induction of antigen-positive cell death by the expression of Perforin, but not DTa, from a DNA vaccine enhances the immune response. Immunology and Cell Biology, 92(4), 359-367. DOI Scopus22 WoS23 Europe PMC21
2008	Grubor-Bauk, B., Arthur, J., & Mayrhofer, G. (2008). Importance of NKT Cells in Resistance to Herpes Simplex Virus, Fate of Virus-Infected Neurons, and Level of Latency in Mice. Journal of Virology, 82(22), 11073-11083. DOI Scopus41 WoS41 Europe PMC36
2003	Grubor-Bauk, B., Simmons, A., Mayrhofer, G., & Speck, P. (2003). Impaired clearance of herpes simplex virus type 1 from mice lacking CD1d or NKT cells expressing the semivariant Vα14-Jα 281 TCR. Journal of Immunology, 170(3), 1430-1434. DOI Scopus172 WoS162 Europe PMC130
-	Abayasingam, A., Balachandran, H., Agapiou, D., Rodrigo, C., Keoshkerian, E., Li, H., . . . Group, C. O. S. I. N. S. (n.d.). Long-Term Persistence of Neutralizing Memory B Cells in SARS-CoV-2.
-	Garcia Valtanen, P., Hope, C. M., Masavuli, M. G., Yeow, A., Balachandran, H., Mekonnen, Z. A., . . . Grubor-Bauk, B. (n.d.). 'One Year Later' - SARS-CoV-2-Specific Immunity in Mild Cases of COVID-19.

Book Chapters

Year	Citation
2017	Tomusange, K., Wijesundara, D., Gowans, E., & Grubor-Bauk, B. (2017). Human rhinovirus-A1 as an expression vector. In M. C. Ferran, & G. R. Skuse (Eds.), Recombinant Virus Vaccines: Methods and Protocols (Vol. 1581, pp. 181-201). UK: Humana Press. DOI

Conference Papers

Year	Citation
2022	Tunbridge, M. J., Perkins, G., Salehi, T., Grubor-Bauk, B., Sim, B., Ying, T., . . . Coates, P. T. (2022). A Prospective Randomised, Controlled Trial Switching Sirolimus for Mycophenolate to Enhance Immunological Responses to Third Dose COVID-19 Vaccination in Kidney Transplant Recipients with Poor Baseline Humoral Immunity. In AMERICAN JOURNAL OF TRANSPLANTATION Vol. 22 (pp. 1095). ELECTR NETWORK: WILEY.
2022	Perkins, G. B., Tunbridge, M., Salehi, T., Chai, C., Hope, C. M., Garcia-Valtanen, P., . . . Coates, P. (2022). Sirolimus Use is Associated with an Improved Immune Response to COVID-19 Vaccination in Kidney Transplant Recipients. In AMERICAN JOURNAL OF TRANSPLANTATION Vol. 22 (pp. 873). WILEY.
2016	Wijesundara, D., Grubor-Bauk, B., Gargett, T., Yu, W., & Gowans, E. (2016). A cytolytic DNA vaccine to target cross-presentation of dendritic cells. In EUROPEAN JOURNAL OF IMMUNOLOGY Vol. 46 (pp. 1060-1061). Melbourne, AUSTRALIA: WILEY-BLACKWELL.

Conference Items

Year	Citation
2022	Perkins, G., Tunbridge, M., Salehi, T., Chai, C. S., Hope, C. M., Garcia-Valtanen, P., . . . Coates, A. O. T. (2022). MTOR Inhibitors Promote Highly Functional T Cell Immunity in Kidney Transplant Recipients Vaccinated Against COVID-19. Poster session presented at the meeting of TRANSPLANTATION. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
2017	Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2017). Novel DNA vaccine formulations encoding secreted HCV-E1/E2 fused to the IMX313 oligomerisation domain are immunogenic in mice. Poster session presented at the meeting of 12th Annual Scientific Meeting of the Australian Centre for HIV and Hepatitis Virology.
2017	Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2017). Novel DNA vaccine formulations encoding secreted HCV-E1/E2 fused to the IMX313 oligomerisation domain are immunogenic in mice. Poster session presented at the meeting of Adelaide Immunology Retreat. Nuriootpa.
2017	Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2017). Novel DNA vaccine formulations encoding secreted HCV-E1/E2 fused to the IMX313 oligomerisation domain are immunogenic in mice. Poster session presented at the meeting of Florey Postgraduate Research Conference.
2017	Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2017). Enhancing the immunogenicity of HCV vaccines by fusing E1/E2 to the IMX313P multimerization technology. Poster session presented at the meeting of 24th International Symposium on Hepatitis C Virus and Related Viruses. Hyannis, Cape Cod, Massachusetts, USA.
2017	Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2017). Novel DNA vaccines encoding secreted HCV-E1/E2 fused to the IMX313 oligomerisation domain are immunogenic in mice. Poster session presented at the meeting of The Queen Elizabeth Hospital (TQEH) Research Day. Adeleide, Australia.
2017	Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2017). Enhancing the immunogenicity of HCV vaccines by fusing E1/E2 to the IMX313P oligomerisation technology. Poster session presented at the meeting of 9th Australasian Virology Society Meeting.
2016	Tomusange, K., Wijesundara, D., Gummow, J., Gowans, E. J., & Grubor-Bauk, B. (2016). Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits protective HIV-specific immune responses. Poster session presented at the meeting of Abstracts of the 2016 Conference on HIV Research for Prevention (HIV R4P), as published in Aids Research and Human Retroviruses. Chicago, IL: Mary Ann Liebert. DOI
2016	Khamis, T., Wijesundara, D., Gummow, J., Garrod, T., Li, Y., Gray, L., . . . Gowans, E. (2016). HIV-Tat Fused to the Oligomerisation Domain of the C4-binding Protein Is Highly Immunogenic and Controls EcoHIV Challenge in Mice. Poster session presented at the meeting of AIDS RESEARCH AND HUMAN RETROVIRUSES. Chicago, IL: MARY ANN LIEBERT, INC.
2016	Masavuli, M. G., Wijesundara, D. K., Grubor-Bauk, B., & Gowans, E. J. (2016). A novel DNA-based virus-like particle (VLP) vaccine against hepatitis C.. Poster session presented at the meeting of Florey Postgraduate Research Conference.
2016	Masavuli, M. G., Wijesundara, D. W., Grubor-Bauk, B., & Gowans, E. J. (2016). A DNA-based virus-like particle (VLP) vaccine against the hepatitis C virus. Poster session presented at the meeting of The Queen Elizabeth Hospital (TQEH) Research Day. Adelaide.
2015	Masavuli, M. G., Grubor-Bauk, B. G., Wijesundara, D. K., & Gowans, E. J. (2015). A novel DNA-based virus-like particle (VLP) vaccine for hepatitis C virus. Poster session presented at the meeting of Florey Postgraduate Research Conference. AdelaIide.
2015	Masavuli, M. G., Wijesundara, D. K., grubor-bauk, B., & gowans, E. G. (2015). A novel DNA-based virus-like particle vaccine for hepatitis C virus. Poster session presented at the meeting of The Queen Elizabeth Hospital (TQEH) Research Day 2015. Adelaide.
2013	Loveland, B. E., Latour, P., Roberts, S. K., Gordon, A., Kemp, W., Kitson, M., . . . Gowans, E. J. (2013). A Phase I clinical trial of cellular immunotherapy for persistent Hepatitis C infection. Poster session presented at the meeting of Clinical and Experimental Pharmacology and Physiology. Hangzhou, Peoples Republic of China: Wiley-Blackwell.

Theses

Year Citation
2018 Masavuli, M. G. (2018). Novel DNA Vaccine Formulations Against
Hepatitis C Virus. (PhD Thesis).

Year	Citation
2018	Masavuli, M. G. (2018). Novel DNA Vaccine Formulations Against Hepatitis C Virus. (PhD Thesis).

2019 B Grubor-Bauk, EJ Gowans, DK Wijesundara ($200,000) "A novel Zika virus DNA vaccine that provides complete protection from infection." Commercial Accelerator Scheme, Adelaide Enterprise, University of Adelaide and The Hospital Research Foundation

2019 B Grubor-Bauk "Barbara Kidman Women's Fellowship" ($60,000). University of Adelaide and The Hospital Research Foundation

2019 DK Wijesundara, EJ Gowans, S Robertson, B Grubor-Bauk, A Shrestha "A pre-clinical evaluation of an innovative DNA-based vaccination regimen to protect women of childbearing age against Zika virus during sexual transmission." Ch7 Children's Research Foundation and The Hospital Research Foundation ($200,000)

2018 Z Kopecki, B Grubor-Bauk, KA Fenix, D Wijesundara, A Cowin ($28,619) "Identification of a diagnostic marker for assessment and management of psoriasis. New Adventures Fund UniSA and The Hospital Research Foundation

2018 EJ Gowans, B Grubor-Bauk, D Wijesundara, N Eyre ($88,000) "HCV challenge studies in vaccinated mice’ . Australian Centre for HIV and Hepatitis Virology Research (ACH2).

2016-2018 EJ Gowans, B Grubor-Bauk, D Wijesundara. ($293,880): A DNA vaccine for Zika virus. National Foundation for Medical Research and Innovation (NFMRI)

2017 EJ Gowans, B Grubor-Bauk, D Wijesundara ($85,000) A multigenotypic HCV DNA Vaccine. Australian Centre for HIV and Hepatitis Virology Research (ACH2)

2016-2017 EJ Gowans, B Grubor-Bauk, D Wijesundara ($100,000) "A DNA vaccine to induce protective neutralizing antibodies to the HIV Tat protein." The Hospital Research Foundation

2014 EJ Gowans, B Grubor-Bauk ($100,000) "Optimisation of HCV vaccine design." The Hospital Research Foundation .

2014-2015 EJ Gowans, I Roberts-Thomson, B Grubor-Bauk ($300, 000). “DNA vaccine therapy for HCV.” The Hospital Research Foundation .

2012-2013 E.J. Gowans and B Grubor-Bauk 2012/2013 ($174,000) “Development of a cytolytic HCV vaccine and a novel challenge model to test efficacy.” Australian Centre for HIV and Hepatitis Virology Research (ACH2).

Current Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2024	Principal Supervisor	Harnessing the potential of mRNA vaccines against Hepatitis C Virus	Doctor of Philosophy	Doctorate	Full Time	Mr John Henrik Johansson
2023	Co-Supervisor	The Effect of Sirolimus on Enhancing COVID-19 Vaccine Response in Transplant Recipients	Doctor of Philosophy	Doctorate	Full Time	Mr Cheng Sheng Chai
2022	Principal Supervisor	A Trivalent Vaccine for Clinically-Important Flaviviruses.	Doctor of Philosophy	Doctorate	Full Time	Mr Ryan Santos
2021	Principal Supervisor	The development of 'next generation' DNA-based vaccine against SARS-CoV-2	Doctor of Philosophy	Doctorate	Full Time	Miss Zahraa Nima Saeed Al-Delfi

Past Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2015 - 2019	Co-Supervisor	Pre-Clinical Evaluation of a Vaccination Strategy to Induce Liver Resident Memory T Cells against Hepatitis C Virus	Doctor of Philosophy	Doctorate	Full Time	Mr Zelalem Addis Mekonnen
2015 - 2016	Co-Supervisor	Strategies for the development of recombinant porcine adenovirus-based vaccines against Hepatitis C virus.	Master of Philosophy (Medical Science)	Master	Full Time	Mr Harshwardhan Jagdale
2014 - 2018	Co-Supervisor	Novel DNA Vaccine Formulations Against Hepatitis C Virus	Doctor of Philosophy	Doctorate	Full Time	Dr Makutiro Ghislain Masavuli
2013 - 2016	Co-Supervisor	Novel Recombinant DNA and Live Virus Vaccines to Prevent or Control HIV-1 Infection	Doctor of Philosophy	Doctorate	Full Time	Mr Khamis Tomusange
2012 - 2014	Co-Supervisor	Evaluating the Immuno-modulatory Effects of a Natural Adjuvant as a Novel Vaccine Strategy	Doctor of Philosophy	Doctorate	Full Time	Miss Tamsin Jade Garrod
2012 - 2013	Co-Supervisor	Optimising DNA vaccine technology to prevent HIV-1 Infection	Doctor of Philosophy	Doctorate	Full Time	Miss Tessa Gargett
2012 - 2017	Co-Supervisor	The Development of a Multi-Antigenic Cytolytic DNA Vaccine against HCV	Doctor of Philosophy	Doctorate	Full Time	Dr Jason Anthony Gummow
2010 - 2012	Co-Supervisor	Suicide Genes in a Novel Vaccination Strategy for Hepatitis C	Master of Philosophy	Master	Full Time	Mr Hugh Francis Trahair

Position: Externally-Funded Research Fellow (D)
Phone: 82227368
Email: branka.grubor@adelaide.edu.au
Fax: 82227872
Campus: The Queen Elizabeth Hospital
Building: QEH- Basil Hetzel Institute, floor 1
Org Unit: Surgical Specialities

Associate Professor Branka Grubor-Bauk

Language Competencies